Benitec Biopharma Inc.
BNTCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. At a $437.2M market cap, Benitec Biopharma Inc. ranks as a small-cap company within healthcare. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Market Cap
$437.2M
Beta
0.27
P/E (TTM)
—
P/E (Fwd)
-1.35
EPS (TTM)
$-0.93
EPS (Fwd)
$-9.42
ROE
-29.6%
ROA
-19.9%
Cash
$184.8M
Total Debt
$876,000
Free CF
-$7.1M
52W Change
-5.0%
Annual Financials
Cash vs Debt
Where BNTC stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, BNTC finished 1.84% above its 150-day moving average ($11.95) and 0.41% above its 200-day moving average ($12.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNTC overbought or oversold?
At the September 1, 2026 close, BNTC's RSI(14) was 37.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Benitec Biopharma Inc. holds $184.8M in cash against $876K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$7.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -29.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $73K (2022) to $0 (2025), a 100% decline worth watching.
BNTC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Benitec Biopharma Inc. and its sector.